Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916617 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00916617 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 62 participants.
The verdict
NCT00916617, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.
Interventions
- DRUG bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916617
The ClinicalTrials.gov registry entry for NCT00916617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bapineuzumab is the first listed.
NCT00916617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916617 about?
NCT00916617 is a clinical study titled "Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab". This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses)....
What is the current status of trial NCT00916617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2009-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00916617?
The interventions under investigation include: bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT00916617?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.